Literature DB >> 26374137

Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma.

Meredith C Mason1,2, Nader N Massarweh1,2,3, Aitua Salami1, Mark A Sultenfuss4, Daniel A Anaya1,2,3.   

Abstract

BACKGROUND: Transarterial chemoembolization (TACE) is the most common treatment for patients with unresectable hepatocellular carcinoma (HCC). Post-embolization syndrome (PES) is a common post-TACE complication. The goal of this study was to evaluate PES as an early predictor of the long-term outcome.
METHODS: A retrospective cohort study of HCC patients treated with TACE at a tertiary referral centre was performed (2008-2014). Patients were categorized on the basis of PES, defined as fever with or without abdominal pain within 14 days of TACE. The primary outcome was overall survival (OS). Multivariate Cox regression was done to examine the association between PES and OS.
RESULTS: Among 144 patients, 52 (36.1%) experienced PES. The median follow-up for the cohort was 11.4 months. The median and 3-year OS rates were 16 months and 18% in the PES group versus 25 months and 41% in the non-PES group (log rank, P = 0.027). After multivariate analysis, patients with PES had a significantly increased risk of death [hazard ratio 2.0 (95%CI 1.2-3.3), P = 0.011].
CONCLUSIONS: PES is a common complication after TACE and is associated with a two-fold increased risk of death. Future studies should incorporate PES as a relevant early predictor of OS and examine the biological basis of this association.
© 2015 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2015        PMID: 26374137      PMCID: PMC4644367          DOI: 10.1111/hpb.12487

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  43 in total

1.  Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome.

Authors:  Sabeen Dhand; Ramona Gupta
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

2.  Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients.

Authors:  Katerina Malagari; Mary Pomoni; Themistoklis N Spyridopoulos; Hippokratis Moschouris; Alexis Kelekis; Spyros Dourakis; Efthymia Alexopoulou; John Koskinas; Michalis Angelopoulos; John Kornezos; Anastasia Pomoni; Savvas Tandeles; Athanasios Marinis; Spyros Rizos; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2010-12-24       Impact factor: 2.740

3.  Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.

Authors:  Thomas J Vogl; Johannes Lammer; Riccardo Lencioni; Katerina Malagari; Anthony Watkinson; Frank Pilleul; Alban Denys; Clara Lee
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

4.  Report of the 16th follow-up survey of primary liver cancer.

Authors:  Iwao Ikai; Shigeki Arii; Takafumi Ichida; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2005-07-18       Impact factor: 4.288

Review 5.  Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review.

Authors:  Robert Martin; David Geller; Joseph Espat; David Kooby; Marty Sellars; Robert Goldstein; David Imagawa; Charles Scoggins
Journal:  Hepatogastroenterology       Date:  2012 Jan-Feb

6.  Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.

Authors:  Giada Pietrosi; Roberto Miraglia; Angelo Luca; Giovanni Battista Vizzini; Daniela Fili'; Volpes Riccardo; Adele D'Antoni; Ioannis Petridis; Luigi Maruzzelli; Domenico Biondo; Bruno Gridelli
Journal:  J Vasc Interv Radiol       Date:  2009-06-04       Impact factor: 3.464

Review 7.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

8.  Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.

Authors:  J W Chung; J H Park; J K Han; B I Choi; M C Han; H S Lee; C Y Kim
Journal:  Radiology       Date:  1996-01       Impact factor: 11.105

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.

Authors:  Beatrijs A Seinstra; Luc Defreyne; Bieke Lambert; Marnix G E H Lam; Helena M Verkooijen; Karel J van Erpecum; Bart van Hoek; Arian R van Erkel; Minneke J Coenraad; Imad Al Younis; Hans van Vlierberghe; Maurice A A J van den Bosch
Journal:  Trials       Date:  2012-08-23       Impact factor: 2.279

View more
  16 in total

1.  Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma.

Authors:  Ahmed Shehta; Jeong-Moo Lee; Kyung-Suk Suh; Hyo-Cheol Kim; Suk Kyun Hong; Jae-Hyung Cho; Nam-Joon Yi; Kwang-Woong Lee
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2020-11-30

2.  Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC.

Authors:  K J Hartrumpf; S Marquardt; T Werncke; T Murray; M M Kirstein; A Vogel; F Wacker; T Rodt
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-14       Impact factor: 4.553

3.  A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization.

Authors:  Ali Morshid; Khaled M Elsayes; Ahmed M Khalaf; Mohab M Elmohr; Justin Yu; Ahmed O Kaseb; Manal Hassan; Armeen Mahvash; Zhihui Wang; John D Hazle; David Fuentes
Journal:  Radiol Artif Intell       Date:  2019-09-25

4.  Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience.

Authors:  Chandan K Kedarisetty; Sipra Bal; Subhashree Parida; Mayank Jain; Ajeet S Bhadoria; Joy Varghese; Jayanthi Venkataraman
Journal:  J Clin Exp Hepatol       Date:  2020-10-27

5.  N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization.

Authors:  Sith Siramolpiwat; Thanachai Punjachaipornpon; Bubpha Pornthisarn; Ratha-Korn Vilaichone; Soonthorn Chonprasertsuk; Anupong Tangaroonsanti; Patommatat Bhanthumkomol; Achara Phumyen; Atipat Yasiri; Mayurachat Kaewmanee
Journal:  Dig Dis Sci       Date:  2019-05-09       Impact factor: 3.487

6.  Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study.

Authors:  Cheng Wu Tang; Ming Zhu; Wen Ming Feng; Ying Bao; Yin Yuan Zheng
Journal:  Drug Des Devel Ther       Date:  2016-08-03       Impact factor: 4.162

7.  Health education helps to relieve postembolization pain during hepatic arterial chemoembolization therapy.

Authors:  Zi Xuan Wang; Lin Li; Feng Ying Tao
Journal:  J Pain Res       Date:  2018-09-28       Impact factor: 3.133

8.  Determination of Risk Factors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma.

Authors:  Tian-Cheng Wang; Zi-Shu Zhang; Yu-Dong Xiao
Journal:  J Pain Res       Date:  2020-03-27       Impact factor: 3.133

9.  Identifying predictors and evaluating the role of steroids in the prevention of post-embolization syndrome after transarterial chemoembolization and bland embolization.

Authors:  Rohit Agrawal; Muhammad Majeed; Sheeba-Ba Aqeel; Yuchen Wang; Zohaib Haque; Yazan Abu Omar; Shristi Banskota Upadhyay; Thomas Gast; Bashar M Attar; Seema Gandhi
Journal:  Ann Gastroenterol       Date:  2020-12-12

10.  Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients.

Authors:  Yaohong Liu; Wensou Huang; Mingji He; Hui Lian; Yongjian Guo; Jingjun Huang; Jingwen Zhou; Kangshun Zhu
Journal:  Oncol Res       Date:  2018-07-13       Impact factor: 5.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.